stockrowIllumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
Follow ILMN
Alert me
Illumina, Inc. (ILMN) Total debt
Illumina, Inc.'s total debt at the end of fiscal 2025 was $1.5B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.8B. Over the past ten years it has ranged from $1.1B (fiscal 2016) to $2.0B (fiscal 2018); the current reading is higher than 82% of that period. Illumina, Inc. ranks 13th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.5B | 0.00% |
| FY2024 | $1.5B | 0.07% |
| FY2023 | $1.5B | 0.13% |
| FY2022 | $1.5B | (12.27%) |
| FY2021 | $1.7B | 43.16% |
| FY2020 | $1.2B | (0.17%) |
| FY2019 | $1.2B | (40.61%) |
| FY2018 | $2.0B | 67.53% |
| FY2017 | $1.2B | 12.67% |
| FY2016 | $1.1B | (2.99%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $1.8B | 19.99% |
| Jun 2026 | $1.5B | 0.07% |
| Mar 2026 | $1.5B | 0.00% |
| Dec 2025 | $1.5B | 49.90% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IQV IQVIA Holdings Inc. compare | $16.1B |
| DGX Quest Diagnostics Incorporated compare | $5.6B |
| LH Labcorp Holdings Inc. compare | $5.3B |
| WAT Waters Corporation compare | $4.9B |
| A Agilent Technologies, Inc. compare | $3.6B |
| MTD Mettler-Toledo International, Inc. compare | $2.1B |
| ILMN Illumina, Inc. | $1.8B |
| GH Guardant Health, Inc. compare | $1.5B |
| IDXX IDEXX Laboratories, Inc. compare | $374.9M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ILMN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement